Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00506597 · ClinicalTrials.gov registry record · NA
Erwinase Study in Patients With Acute Lymphoblastic Leukemia
A NA study of Leukemia, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 33
- Enrollment target
- 1
- Study location
NCT00506597: Completed NA study of Leukemia, sponsored by M.D. Anderson Cancer Center.
NCT00506597 is a NA study of Leukemia that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 33 participants, below the 487-participant average among 233 other Leukemia trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00506597, a NA study of Leukemia, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 33 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical research study is to allow doctors to use Erwinia L-Asparaginase (Erwinase®) as a replacement for patients who are allergic to E.coli L-asparaginase or Pegylated E.coli L-asparaginase as part of the treatment for acute lymphoblastic leukemia (ALL) or T or B cell lymphoma. This trial was part of a multi institutional effort by the drug company to make Erwinase available for use.
Primary Outcome
Toxicity data collected and reported as adverse events during the study period. See Adverse Event section for reporting.
Conditions Studied
Interventions
- DRUG Erwinase
Study Locations (1)
Texas
- UT MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2007-05 |
| Est. Completion | 2012-02 |
| Phase | NA |
What the finished NCT00506597 record still lists
NCT00506597 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 487-participant average among 233 other Leukemia trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Leukemia appearing as the primary indexed condition, and to 1 intervention - of which Erwinase is the first listed.
NCT00506597 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT00506597 about?
NCT00506597 is a clinical study titled "Erwinase Study in Patients With Acute Lymphoblastic Leukemia". The goal of this clinical research study is to allow doctors to use Erwinia L-Asparaginase (Erwinase®) as a replacement for patients who are allergic to E.coli L-asparaginase or Pegylated E.coli L-asparaginase as part of the treatment for acute lymphoblastic leukemia (ALL) or T or B cell lymphoma. ...
What is the current status of trial NCT00506597?
This trial is currently completed. It is a NA study. The enrollment target is 33 participants. The study started on 2007-05. Estimated completion is 2012-02.
What conditions does trial NCT00506597 study?
This clinical trial studies the following conditions: Leukemia.
What interventions are being tested in trial NCT00506597?
The interventions under investigation include: Erwinase (DRUG).
Who is sponsoring clinical trial NCT00506597?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00506597 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00506597's enrollment target sits among peer trials
33 155th of 233 higher than 78 of 233 other Leukemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Music Therapy Study for Blood Cancer Survivors With Cognitive Difficulties
RECRUITING · NA
-
Spiritual Care Intervention in Adult Patients Diagnosed With Acute Leukemia
RECRUITING · NA
-
I Can Move With Purpose Now! A Pilot Lifestyle Intervention Study in Myeloproliferative Neoplasm Patients
RECRUITING · NA
-
Driving Inclusivity, Validity, and Equity in Research Through Strategic Engagement (DIVERSE)
RECRUITING · NA
-
HEME Home Transfusion Program
RECRUITING · NA
-
Effects of Using a Storybook, to Explain Leukemia to Children Versus the Standard Child Life Intervention, on Parental Stress.
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia